Vaxart, Inc. · OTC:VXRT
Vaxart — Aviragen Therapeutics — Merger or Acquisition (October 2017)
12 slides from Vaxart's merger presentation, Oct 30, 2017
Slide 1: Aviragen Therapeutics
AVIRAGEN THERAPEUTICS ART October 30, 2017
Slide 2: Safe Harbor
Safe Harbor a This presentation contains forward-looking statements about Aviragen Therapeutics, Inc. and Vaxart Inc., and their respective businesses, business prospects, strategy and plans, including but not limited to statements regarding anticipated preclinical and clinical drug development acti
Slide 3: Additional Information About the Merger and Where to Find It
Additional Information About the Merger and i) Where to Find It VAXART In connection with the merger, Aviragen and Vaxart intend to file relevant materials with the Securities and Exchange Commission, or the SEC, including a registration statement on Form S-4 that will contain a prospectus and a joi
Slide 4: About the Transaction
About the Transaction gp VAXART * Aviragen Therapeutics, Inc. valuation S6OM * Vaxart, Inc. valuation $90M * Aviragen stockholders 40%/Vaxart stockholders 60% * Seven board members — three from Aviragen * Company name will be Vaxart * Proposed NASDAQ ticker — “VXRT” * Approximately $30M in cash proj
Slide 5: Oral Recombinant Vaccines
ORAL RECOMBINANT VACCINES = th —$ VAART — INNOVATIVE | TABLET OFFERS VACCINE PLATFORM ADVANTAGES Room temperature-stable tablet Designed for wide range of recombinant antigens Broad immune responses Ease of distribution, administration - Systemic & mucosal Does not need to fit normal vaccine immuniz
Slide 6: Oral Recombinant Vaccine Platform
Oral Recombinant Vaccine Platform ip Non-Replicating Ad5 Delivers Antigen + Adjuvant VAXART VACCINE ANTIGEN * Gene for protein antigen VACCINE * Released in lleum generates - Influenza HA Ad5 VECTOR broad immune responses - Norovirus VP2 © Replication ra ? | _RSVF protein deficient Snare > ‘ | ( oe
Slide 7: Global Vaccines Market: $30 Billion+ Annual Sales
Global Vaccines Market: $30 Billion+ Annual Sales eb VAXART “Vaccines are among big pharma’s best selling products” — FT, April 26 2016 Vaccine Growth Trends — Innovation — Elderly/Adult Vaccination — Vaccination for New Diseases — Emerging Market Expansion Vaxart Platform: Engine for Hi-Value Vacci
Slide 8: Veteran Management Team with Deep Experience in Vaccines and Immunology
Veteran Management Team with Deep i) Experience in Vaccines and Immunology UANART RELEVANT EXPERIENCE MANAGEMENT TEAM (YEARS) COMPANIES EXPERTISE Vaccines, Mucosal tb Novartis TRINTY® Delivery of Biopharmaceuticals WOUTER LATOUR, MD MBA CEO 20 SmithKline Beecham SEAN TUCKER, PHD S\ ix @GENTERIC Muco
Slide 9: Robust Antiviral Clinical Pipeline Focused on Both Prophylactic and Therapeutic Products
Robust Antiviral Clinical Pipeline Focused on Both fp Prophylactic and Therapeutic Products VAXART Prophylactic Norovirus » Influenza 2 RSV Therapeutic HPV Vaccine Small Molecules HPV (BTAO74) Rhinovirus (Vapendavir) Ss Shs >D === > EA ——k—E RSV (non-F) Ee Inavir® Dn a Relenza® 1) Monovalent GI.1 no
Slide 10: Norovirus: Tablet is Key Differentiator
Norovirus: Tablet is Key Differentiator ip oo i Major ‘Consumer’ Opportunity in Food and Travel Sector VAMART Disease Burden ) oe 7#20M * Norovirus leads to majority of Acute Gastroenteritis — 19-21 Million Cases, 56,000-71,000 Hospitalizations ‘About 20 milion people get sick from norovirs each yea
Slide 11: Safety and Broad Immune Responses in Multiple Trials
Safety and Broad Immune Responses in Multiple Trials ip More than 300 Subjects Dosed to Date VAXART CLINICAL TRIALS Tablet Vaccines Flu RSV rus SUBJECTS DOSED 176 46 106 SAFETY Favorable safety and tolerability profile EFFICACY Reduction in influenza illness comparable with the leading marketed quad
Slide 12: Clinical & Regulatory Milestones
Clinical & Regulatory Milestones ep VAXART Recently Completed Y 93 2017- Reported positive top-line data from Phase 1b norovirus vaccine safety and immunogenicity trial Y Q3 2017- Reported positive top-line data from Phase 2 influenza vaccine challenge trial Upcoming * Q4 2017 - Complete enrollment
Aviragen Therapeutics — Merger or Acquisition (October 2017) on 6ix